1Brindle JT,Nicholson JK, Schofield PM,et al. Application of chemo met- rics to NMR spectroscopic data to investigate a relationship between human serum metabolic profile and hypertension [J]. Analyst, 2003, 128( 1 ) :32.
7Holmes E, Antti H. Chemometric contributions to the evolution of metabo- nomics: Mathematical solutions to characterizing and interpreting complex biological NMR spectra[J]. Analyst, 2002, 127(12):1549.
8Nicholson JK, Holmes E, Lindon JC, etal. The challenges of modeling mammalian biocomplexity [ J ]. Nat Biotecho1,2004 ,22 (10).
4Reddy KS. The preventive polypill-much promise, insufficient evidence[J]. N Engl J Med, 2007, 356 (3): 212.
5Yusuf S. Two decades of progress in preventing vasculardisease[J]. Lancet, 2002, 360(9326):2-3.
6Wald N J, Law MR. A strategy to reduce cardiovascular disease by more than 80% [ J ]. BMJ, 2003,326 (7404) :1419.
7Indian Polycap Study (TIPS), Yusuf S, Pais P, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS) : a phase Ⅱ , double-blind, randomised trial [ J ]. Lancet, 2009,373 ( 9672 ): 1341 - 1351.
9Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill [ J ]. Eur Heart J, 2006, 27(14) :1651-1656.
10Rastegarpanah M, al. A new horizon cular disease, can polypill" [ J ] ? Arch Malekzadeh F, Thomas GN, et n primary prevention of cardiovaswe prevent heart attack by " heart Iran Med, 2008,11 (3):306-313.
